It is well documented that patients with HR+ breast cancer are less likely than those with HER2+ or triple-negative breast cancer to achieve a pCR after treatment with neoadjuvant chemotherapy (NAC) [7, 16, 17]. This evidence concerns the gene ERBB2 and breast cancer.